Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population

被引:2
|
作者
Hu, Xue [1 ]
Ding, Wei [2 ]
Jin, Xinye [3 ]
Wang, Jia [4 ]
Zou, Dajin [5 ]
Chen, Yue [6 ]
机构
[1] Shidong Hosp, Dept Endocrinol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Geriatr, Shanghai, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China
[4] Gen Hosp Jinan Mil Reg Chinese Peoples Liberat Ar, Dept Endocrinol, Jinan, Shandong, Peoples R China
[5] Second Mil Med Univ, Dept Endocrinol, Changhai Hosp, 168 ChangHai Rd, Shanghai 200433, Peoples R China
[6] Shanghai Baoshan Tradit Chinese Med Integrated Ho, Dept Endocrinol, 181 YouYi Rd, Shanghai 201900, Peoples R China
来源
POSTEPY DERMATOLOGII I ALERGOLOGII | 2018年 / 35卷 / 01期
关键词
acne; SRD5A2; gene; V89L polymorphism; (TA)n repeat polymorphism; PROSTATE-CANCER RISK; STEROID; 5-ALPHA-REDUCTASE; ASSOCIATION; TYPE-2;
D O I
10.5114/ada.2018.73162
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Introduction: Several studies have reported that the V89L and TA repeat polymorphisms [(TA)n] of the SRD5A2 gene were associated with SRD5A2 activity. The activity of dihydrotestosterone, which is converted from testosterone by SRD5A2, is responsible for sebum secretion and the formation of acne. We hypothesized that abnormalities in SRD5A2 action could contribute to the formation of acne. Aim: To study whether the structural change of the SRD5A2 gene may affect the risk of acne in patients with normal serum testosterone levels. Material and methods: Genotyping of rs523349 and (TA) n of SRD5A2 was performed in 49 Chinese acne patients with significant improvements with SRD5A2 inhibitor-finasteride but normal serum testosterone levels, and in 50 healthy Chinese age-matched controls without acne. Results: There was no significant difference between the two groups in the frequencies of V and L alleles and VV, VL, and LL genotypes of V89L (chi(2) test, p > 0.5). (TA) n polymorphic repeat sites are 5 alleles (TA0, TA3, TA6, TA9, TA12) in our population. The differences in S and L allele frequencies between the two groups were statistically significant (p < 0.005). People with a longer (n >= 6) allele of the (TA) n repeat polymorphism had a higher risk of having acne than those with a shorter (n < 6) allele (OR = 3.52, 95% CI: 1.73-7.16). Conclusions: This study suggests that SRD5A2 polymorphisms might be associated with acne risk. This is the first report focusing on the Chinese population according to our knowledge. Further large sample studies may be required to confirm the association and to assess any interactions with environmental factors.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 47 条
  • [31] Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population
    Paz-y-Mino, Cesar
    Witte, Tania
    Robles, Paulo
    Llumipanta, William
    Diaz, Myriam
    Arevalo, Melissa
    CANCER GENETICS AND CYTOGENETICS, 2009, 189 (02) : 71 - 76
  • [32] The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
    Onen, Ilke Hacer
    Ekmekci, Abdullah
    Eroglu, Muzaffer
    Polat, Fazli
    Biri, Hasan
    DNA AND CELL BIOLOGY, 2007, 26 (02) : 100 - 107
  • [33] Steroid 5-α reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study
    Pearce, CL
    Makridakis, NM
    Ross, RK
    Pike, MC
    Kolonel, LN
    Henderson, BE
    Reichardt, JKV
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (04) : 417 - 418
  • [34] Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer
    Li, Xia
    Huang, Yan
    Fu, Xuping
    Chen, Chengwen
    Zhang, Deqiang
    Yan, Lili
    Xie, Yi
    Mao, Yanjun
    Li, Yao
    MUTAGENESIS, 2011, 26 (03) : 371 - 383
  • [35] Polymorphic markers in the SRD5A2 gene and prostate cancer risk:: A population-based case-control study
    Hsing, AW
    Chen, C
    Chokkalingam, AP
    Gao, YT
    Dightman, DA
    Nguyen, HT
    Deng, J
    Cheng, JR
    Sesterhenn, IA
    Mostofi, FK
    Stanczyk, FZ
    Reichardt, JKV
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (10) : 1077 - 1082
  • [36] CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population
    Sobti, R. C.
    Onsory, Khadijeh
    Al-Badran, Adnan Issa
    Kaur, Pushpinder
    Watanabe, Masatoshi
    Krishan, A.
    Mohan, Harsh
    DNA AND CELL BIOLOGY, 2006, 25 (05) : 287 - 294
  • [37] The association of steroid 5-alpha reductase type-II gene polymorphisms (A49T and V89L) with prostate cancer risk in African population: A systematic review and meta-analysis
    Ayeni, Timothy Oluwatimileyin
    Bajepade, Tobiloba Isaac
    Akanni, Mosunmola Hannah
    Pirisola, Ayomikun Joshua
    Oluwajembola, Abimbola Mary
    Chinedu, Shalom Nwodo
    SCIENTIFIC AFRICAN, 2024, 26
  • [38] V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
    Nam, RK
    Toi, A
    Vesprini, D
    Ho, M
    Chu, W
    Harvie, S
    Sweet, J
    Trachtenberg, J
    Jewett, MAS
    Narod, SA
    UROLOGY, 2001, 57 (01) : 199 - 204
  • [39] A comprehensive systematic review of studies on the potential of A49T and V89L polymorphism in SRD5AR2 as high susceptibility gene association with benign prostate hyperplasia and prostate cancer
    Maharani, Revina
    Lestari, Hotma
    Dewa, Putra Mahakarya
    Yudisthira, Dewangga
    Amar, Nasim
    Daryanto, Besut
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2025, 96 (01)
  • [40] Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population
    Zhang, Lin-Lin
    Song, Yu
    He, Ling-Ling
    Chen, Guo-Qiang
    Fu, Ji-Cheng
    Liu, Lei
    Xi, Bao
    Wang, Lei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (08): : 8660 - 8676